PHAM QUANG X (CEO and Chairman) sold 12.9% of their position (22.39K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $93.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 3 sales
Filed: 6/11/2026ACC: 0001213900-26-067484
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-22.39K
Net shares
Net seller
$93.3K
Total sold
3
Open market trades
0B · 3S
3
Total transactions
22.39K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
−5.89K
Price / share
$4.38
Trade value
$25.81K
% of position
3.4%
6/8/2026
173.22K→167.33K
Common Stock
Direct
Shares
−12.99K
Price / share
$4.06
Trade value
$52.75K
% of position
7.8%
6/9/2026
167.33K→154.34K
Common Stock
Direct
Shares
−3.50K
Price / share
$4.21
Trade value
$14.73K
% of position
2.3%
6/10/2026
154.34K→150.84K
Total
Net shares
−22.39K
Net value
-$93.29K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/8/2026 | S · Sale | −5.89K | $4.38 | $25.81K | 3.4% | 173.22K | 167.33K |
| Common Stock Direct | 6/9/2026 | S · Sale | −12.99K | $4.06 | $52.75K | 7.8% | 167.33K | 154.34K |
| Common Stock Direct | 6/10/2026 | S · Sale | −3.50K | $4.21 | $14.73K | 2.3% | 154.34K | 150.84K |
| Total | −22.39K | -$93.29K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported